IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Malagola, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.494
AS - Asia 10.412
EU - Europa 8.486
SA - Sud America 2.462
AF - Africa 207
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 16
Totale 39.098
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.208
SG - Singapore 3.643
CN - Cina 3.341
UA - Ucraina 2.353
BR - Brasile 2.061
HK - Hong Kong 1.391
DE - Germania 1.343
IT - Italia 1.050
PL - Polonia 853
FI - Finlandia 681
VN - Vietnam 664
TR - Turchia 466
RU - Federazione Russa 458
GB - Regno Unito 454
IE - Irlanda 389
IN - India 290
SE - Svezia 288
FR - Francia 233
AR - Argentina 149
BD - Bangladesh 137
CA - Canada 127
MX - Messico 102
ZA - Sudafrica 88
IQ - Iraq 76
EC - Ecuador 70
CZ - Repubblica Ceca 64
ID - Indonesia 63
NL - Olanda 62
ES - Italia 55
CO - Colombia 51
AT - Austria 49
JP - Giappone 47
BE - Belgio 45
SA - Arabia Saudita 44
VE - Venezuela 39
UZ - Uzbekistan 36
PY - Paraguay 35
PK - Pakistan 33
MA - Marocco 22
IL - Israele 21
JO - Giordania 21
KE - Kenya 21
EG - Egitto 20
EU - Europa 20
AE - Emirati Arabi Uniti 18
CL - Cile 16
DK - Danimarca 15
UY - Uruguay 15
AU - Australia 14
JM - Giamaica 14
LT - Lituania 14
MU - Mauritius 14
PE - Perù 14
IR - Iran 13
TH - Thailandia 12
AZ - Azerbaigian 11
ET - Etiopia 11
OM - Oman 11
DZ - Algeria 10
KZ - Kazakistan 10
PT - Portogallo 10
TN - Tunisia 10
BG - Bulgaria 9
BO - Bolivia 9
DO - Repubblica Dominicana 9
MY - Malesia 9
GR - Grecia 8
NP - Nepal 8
HN - Honduras 7
KR - Corea 7
PA - Panama 7
AL - Albania 6
BA - Bosnia-Erzegovina 6
PS - Palestinian Territory 6
AM - Armenia 5
CR - Costa Rica 5
KG - Kirghizistan 5
LK - Sri Lanka 5
LV - Lettonia 5
RS - Serbia 5
SN - Senegal 5
CH - Svizzera 4
EE - Estonia 4
HU - Ungheria 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
BB - Barbados 3
CU - Cuba 3
HR - Croazia 3
KW - Kuwait 3
LB - Libano 3
NI - Nicaragua 3
NO - Norvegia 3
RO - Romania 3
TT - Trinidad e Tobago 3
AO - Angola 2
CI - Costa d'Avorio 2
GE - Georgia 2
GY - Guiana 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 39.078
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.001
Singapore 1.623
Jacksonville 1.615
Fairfield 1.565
Hong Kong 1.388
Houston 1.330
Ashburn 1.245
Ann Arbor 1.125
Warsaw 838
Princeton 736
Cambridge 734
Wilmington 730
Beijing 642
Chandler 629
Seattle 628
Nanjing 538
New York 453
Dublin 384
Istanbul 349
Los Angeles 336
Helsinki 289
Munich 271
Des Moines 253
Nanchang 231
Ho Chi Minh City 228
Brescia 221
Dallas 216
São Paulo 187
The Dalles 170
Buffalo 154
Moscow 148
Changsha 144
Redondo Beach 143
Hanoi 134
Jinan 129
Shenyang 121
Milan 119
Hebei 118
Tianjin 115
Shanghai 114
Dearborn 110
San Diego 107
San Francisco 101
Turku 89
Boardman 88
Jiaxing 85
Chicago 83
Hangzhou 72
Kunming 66
Kocaeli 64
London 64
Brooklyn 62
Santa Clara 58
Nuremberg 56
Ningbo 55
Rio de Janeiro 55
Verona 55
Brasília 51
Brno 50
Regensburg 50
Guangzhou 49
Zhengzhou 49
Johannesburg 46
Brussels 45
Belo Horizonte 42
Curitiba 42
Pune 42
Toronto 40
Tokyo 39
Rome 38
Denver 37
Mexico City 36
Lanzhou 35
Atlanta 34
Boston 33
Tashkent 33
Phoenix 31
Chennai 30
Taizhou 30
Biên Hòa 29
Montreal 29
Orem 28
Stockholm 27
Da Nang 26
Haikou 26
Norwalk 26
Orange 26
Porto Alegre 26
Frankfurt am Main 25
Grafing 25
Poplar 25
Baghdad 24
Guayaquil 23
Salvador 23
Vienna 23
Charlotte 22
Dong Ket 22
Manchester 22
Ribeirão Preto 22
Romola 22
Totale 25.067
Salva come PNG Salva come JPEG
Nome #
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis 300
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 292
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 272
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 269
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 258
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 225
Zebrafish disease models in hematology: Highlights on biological and translational impact 215
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 192
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 183
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 181
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 174
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 173
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 173
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 168
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 164
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 157
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 156
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 156
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 154
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 152
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 151
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 151
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 148
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 147
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 147
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 145
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 143
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 142
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 142
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 141
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 140
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 140
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 139
Central nervous system angiitis in Hodgkin's disease. 138
Advances in CMV Management: A Single Center Real-Life Experience 138
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 137
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 137
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 137
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 134
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 134
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 134
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 134
Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells 134
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor? 133
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 132
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. 131
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 130
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 129
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 128
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 127
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 127
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 127
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 127
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 126
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia 125
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 125
Advances in the treatment of monoclonal gammapathies: the emerging role of targeted therapy in plasma cell dyscrasias. 124
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 123
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 123
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse 123
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 122
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 121
Expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study. 121
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 121
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. 120
Low dose AraC for Myelodysplastic Syndromes: is it still a current therapy ?. 120
Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. 118
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 118
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 118
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 118
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 117
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 117
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 117
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 116
Acute myeloid leukemia in the elderly: results obtained with conventional chemotherapy 116
Conditioning regimens in acute myeloid leukemia. 116
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 116
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 116
AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act . 116
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 115
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 115
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 115
Liposomal daunorubicin (DAUNOXOME) for treatment of relapsed meningeal acute myeloid leukemia. 115
Treatment of Chronic Myeloid Leukemia elderly patients in the Tyrosine Kinase Inhibitor era. 115
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 115
Ethical and legal issues in haematopoietic stem cells (HSC) donation: the controversial and problematic aspects in minors 115
WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia. 114
Brentuximab vedotin in patients with hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four italian centers 114
Changes in Circulating Endothelial Cells Count Could Become a Valuable Tool in the Diagnostic Definition of Acute Graft-Versus-Host Disease. 113
The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era 113
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 112
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients 112
Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 112
Four Drugs combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as induction therapy for newly diagnosed acute myeloid leukemia patients younger than 65 yrs: response and follow up of 127 patients. 112
Liposomal daunorubicin (DaunoXome) for the treatment of relapsed meningeal acute myeloid leukemia. 111
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 111
Expression of Toll-like receptors and Bteherpesvirus reactivation in the early period after allogeneic stem cell transplantation 111
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 110
ACHIEVEMENT OF COMPLETE REMISSION WITH PONATINIB THERAPY FOR PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE REPORT. 110
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 110
Totale 14.021
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.802
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.259 0 0 0 0 0 626 191 625 621 557 459 180
2021/20222.684 121 460 55 130 111 203 128 194 141 365 203 573
2022/20232.153 435 45 53 175 162 597 7 199 259 30 91 100
2023/20242.723 125 72 190 140 130 457 122 93 758 32 40 564
2024/20256.853 62 79 68 775 775 559 640 200 896 446 1.300 1.053
2025/20268.324 1.265 2.060 1.266 2.309 1.273 151 0 0 0 0 0 0
Totale 40.123